Getwell Pharmaceuticals

Getwell Pharmaceuticals is a family-owned specialty pharmaceutical company based in India, established with the mission to provide high-quality oncology drugs to over 20 countries worldwide. With more than two decades of experience, the company has become a leading provider of sterile oncology dosage forms, including liquid vials, lyophilized, and complex novel drug delivery system (NDDS) formulations.

The company operates under the Corporate Identification Number (CIN) U24290DL2017PTC310791, registered on January 19, 2017, in Delhi, India. Its authorized share capital is ₹34.75 crore, with a paid-up capital of ₹32.75 crore. The registered office is located at Flat No 721, Sector 19 Pocket 3, Delhi, Delhi, India, 110075.

As of January 2026, Getwell Pharmaceuticals employs between 100 to 200 individuals. The company's website, worldofgetwell.com, provides further information about its products and services.

Getwell Pharmaceuticals operates manufacturing facilities in Gurgaon, Haryana, and Bawal, Haryana. These plants specialize in the production of sterile oncology dosage forms, including liquid vials, lyophilized products, and complex NDDS-based formulations. The facilities are designed to meet international quality standards, ensuring the production of high-quality pharmaceutical products.

The leadership team at Getwell Pharmaceuticals includes:

• Pankaj Kumar Kansal: Managing Director
• Renu Kansal: Director
• Mini Tandon: Director
• Manas Tandon: Director
• Sonia Ahuja: Company Secretary
• Rakesh Dwivedi: Director
• Prerna Tandon: Director

These individuals bring a wealth of experience and expertise to the company's operations, contributing to its growth and success in the pharmaceutical industry.

Getwell Pharmaceuticals has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained necessary regulatory approvals and market access in these regions, enabling it to export its products to these countries. This expansion reflects the company's commitment to adhering to international quality standards and meeting the diverse needs of patients worldwide.

In addition to its presence in regulated markets, Getwell Pharmaceuticals has made significant inroads into emerging markets across Africa, Latin America, and Southeast Asia. The company's products are prequalified by the World Health Organization (WHO), facilitating access to these regions and ensuring the availability of high-quality oncology drugs to underserved populations. This strategic approach underscores the company's dedication to global health and its mission to provide affordable and effective treatments worldwide.

Getwell Pharmaceuticals has adopted a diversified geographic strategy, expanding its footprint across both regulated and emerging markets. This approach mitigates concentration risk and positions the company to capitalize on growth opportunities in various regions. The strategic direction focuses on increasing market share in existing territories while exploring new markets to enhance global presence and impact.

As of March 2026, Getwell Pharmaceuticals has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA). The company has filed Abbreviated New Drug Applications (ANDAs) for several of its products, seeking approval for marketing in the United States. Additionally, Getwell Pharmaceuticals has submitted Drug Master Files (DMFs) to the FDA, providing detailed information about the manufacturing processes and quality controls of its products. The company has a history of successful FDA inspections, demonstrating its commitment to maintaining high-quality standards in its operations.

Getwell Pharmaceuticals holds prequalification from the World Health Organization (WHO), affirming the quality, safety, and efficacy of its products. The company also possesses Good Manufacturing Practice (GMP) certificates from the European Union (EU), ensuring compliance with stringent manufacturing standards. These certifications reflect the company's dedication to producing high-quality pharmaceutical products that meet international standards.

In India, Getwell Pharmaceuticals has obtained manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), authorizing it to produce pharmaceutical products for domestic and export markets. The company has also secured approvals from state drug controllers and export No Objection Certificates (NOCs), facilitating its operations and exports. These regulatory approvals underscore the company's compliance with national standards and its commitment to delivering safe and effective products.

As of March 2026, Getwell Pharmaceuticals has maintained a clean regulatory record, with no Form 483 observations, warning letters, or import alerts issued by regulatory authorities. This track record reflects the company's adherence to regulatory requirements and its commitment to maintaining high-quality standards in its operations.

In the oncology pharmaceutical sector, Getwell Pharmaceuticals faces competition from both domestic and international companies. While specific market share data is not available, the company's focus on high-quality, sterile oncology dosage forms positions it as a significant player in the market. The company's commitment to research and development, along with its extensive experience, provides a competitive edge in delivering effective treatments to patients worldwide.

Getwell Pharmaceuticals' key differentiators include its specialization in sterile oncology dosage forms, such as liquid vials, lyophilized products, and complex NDDS-based formulations. The company's extensive experience of over two decades in manufacturing these specialized products establishes it as a reliable provider in the oncology sector. Additionally, its global presence and adherence to international quality standards further distinguish the company in the competitive landscape.

Getwell Pharmaceuticals is strategically positioned as a provider of high-quality oncology drugs, focusing on both generics and specialty formulations. The company's future outlook includes expanding its product portfolio, enhancing research and development capabilities, and increasing its presence in emerging markets to meet the growing global demand for oncology treatments.

Getwell Pharmaceuticals has a strong track record in the pharmaceutical industry, with a consistent export volume and a diverse product portfolio. The company's adherence to international quality standards and its commitment to timely delivery and best business practices make it a reliable supplier for importers seeking high-quality oncology drugs.

Importers should verify the following certifications when considering Getwell Pharmaceuticals as a supplier:

• FDA Facility Registration: Confirm the registration status of Getwell Pharmaceuticals' manufacturing facilities with the U.S. Food and Drug Administration (FDA).

• WHO Prequalification: Ensure that the company's products are prequalified by the World Health Organization (WHO), indicating compliance with international quality standards.

• EU GMP Certification: Verify that Getwell Pharmaceuticals holds Good Manufacturing Practice (GMP) certificates from the European Union, ensuring adherence to stringent manufacturing standards.

• ISO Certification: Check for ISO certifications related to quality management systems, which demonstrate the company's commitment to maintaining high-quality standards.

These certifications can typically be verified through the respective regulatory bodies' official websites or by contacting Getwell Pharmaceuticals directly.

When conducting due diligence on Getwell Pharmaceuticals, consider the following steps:

• Regulatory Compliance: Verify the company's compliance with relevant regulatory authorities, including the FDA, WHO, EU, and CDSCO.

• Financial Stability: Review the company's financial statements to assess its financial health and stability.

• Product Quality: Evaluate the quality of the company's products through certifications, inspection reports, and customer feedback.

• Supply Chain Reliability: Assess the company's supply chain capabilities, including production capacity, lead times, and logistics.

• Reputation and References: Seek references from other clients and industry peers to gauge the company's reputation and reliability.

Be vigilant for any red flags, such as unresolved regulatory issues, financial irregularities, or negative feedback from clients. Conducting thorough due diligence will help ensure a successful partnership with Getwell Pharmaceuticals.